52 completed, 7 active not recruiting, 6 terminated, 4 unknown. 34 Not applicable, 24 Phase 1, 4 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 34 | Completed 24, Active not recruiting 4, Terminated 3, Unknown 2, Recruiting 1 |
| Phase 1 | 24 | Completed 20, Terminated 2, Unknown 2 |
| Early Phase 1 | 4 | Completed 4 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Healthy Subject: new trials by email Literature Review of Healthy Subject trials Research Report on Healthy Subject
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bioequivalence Study betweenYHP2406 and YHR2501 in Healthy Subjects YHP2406, YHR2501 - Healthy Subject | Phase 1 | Completed | Yuhan Corporation | 64 | 2025-06-29 | 2025-07-24 |
| To Evaluate the Safety and Tolerability of Multiple Doses of GS3-007a Oral Solution in Healthy Subjects. GS3-007 oral liquid - Healthy Subject | Phase 1 | Completed | Changchun GeneScience Pharmaceutical Co., Ltd. | 36 | 2023-06-19 | 2023-11-09 |
| Validation and Standardization of Test Methods and Evaluators for Testing of Hair Care Range of Products No drug will given - Healthy Subject | Completed | NovoBliss Research Pvt Ltd | 40 | 2023-04-12 | 2023-05-30 | |
| Consumer Assessment of Tobacco Flavor and Odor Behavioral Intervention, Questionnaire Administration - Current Vaper, Healthy Subject | Terminated | Roswell Park Cancer Institute | 29 | 2023-04-03 | 2026-01-06 | |
| Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects Orelabrutinib and placebo (orelabrutinib tablet simulator), Orelabrutinib, Placebo (orelabrutinib tablet simulator) - Healthy Subject | Phase 1 | Unknown | Beijing InnoCare Pharma Tech Co., Ltd. | 48 | 2022-11-19 | 2022-12-21 |
| A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects STSA-1002 Injection, STSA-1005 Injection - Healthy Subject | Phase 1 | Terminated | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 50 | 2022-11-08 | 2024-05-22 |
| A Study of STSA-1002 in Healthy Subjects STSA-1002 Injection, Placebo - Healthy Subject | Phase 1 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 26 | 2022-10-14 | 2023-04-18 |
| GS3-007a Oral Solution in Healthy Subjects GS3-007 oral liquid or Placebo GS3-007 oral liquid oral medication - Healthy Subject | Phase 1 | Completed | Changchun GeneScience Pharmaceutical Co., Ltd. | 96 | 2022-09-22 | 2023-04-11 |
| A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers HMPL-523 - Healthy Subject | Early Phase 1 | Completed | Hutchison Medipharma Limited | 39 | 2022-06-01 | 2023-04-25 |
| An Exploratory Clinical Trial to Evaluate and Compare Safety and Pharmacokinetic Characteristics After Administration of the DWJ1439, DWJ1464, DWC202108 or DWC202109 in Healthy Adult Volunteers Ursodeoxycholic Acid 250 Mg Oral Tablet - Healthy Subject | Phase 1 | Completed | Daewoong Pharmaceutical Co. LTD. | 44 | 2022-01-27 | 2023-04-27 |
| The Effect of the Consumption of 4 Botanical Extracts on Immunity in Healthy Adults (B-4-Immune) Botanical extract - Healthy Subject, Immunity | Not applicable | Unknown | Givaudan France Naturals | 115 | 2021-11-22 | 2021-11-30 |
| A Study of Bioavailability and Food Effect of SACT-1 and Edurant® Tablets in Healthy Adult Volunteers SACT-1, EDURANT 25Mg Tablet - Healthy Subject | Phase 1 | Completed | Aptorum International Limited | 16 | 2021-10-09 | 2022-05-26 |
| Phase I Study to Compare the Pharmacokinetics, Pharmacodynamics, and Safety Between CT-P41 and US-licensed Prolia in Healthy Male Subjects CT-P41, US-licensed Prolia - Healthy Subject | Phase 1 | Completed | Celltrion | 154 | 2021-10-06 | 2023-09-14 |
| Phase 1 Study of 3D229 in Healthy Subjects 3D229, Placebo - Healthy Subject | Phase 1 | Completed | 3D Medicines | 24 | 2021-07-27 | 2022-06-22 |
| A Study of ALS-4 in Healthy Adults Subjects ALS-4, Placebo - Healthy Subject | Phase 1 | Completed | Aptorum International Limited | 72 | 2021-03-20 | 2022-04-25 |
| Fiber and Fish Oil Supplements for the Prevention of Colorectal Cancer Dietary Fiber, Fish Oil, Comparator - Healthy Subject | Not applicable | Completed | Fred Hutchinson Cancer Center | 38 | 2021-01-05 | 2024-09-27 |
| Nipple Aspirate Fluid in Detecting Breast Cancer Aspiration of Breast, Biospecimen Collection - Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 | Not applicable | Completed | Ohio State University Comprehensive Cancer Center | 2 | 2020-12-10 | 2025-02-25 |
| Collection of PBMCs From Healthy Subjects for the Development of Cellular Immunotherapy Product Peripheral blood mononuclear cell apheresis - Healthy Subject | Not applicable | Unknown | Jun Zhu | 172 | 2020-04-01 | 2021-06-09 |
| The Peer Genetic Study Cancer Educational Materials, Questionnaire Administration, Educational Intervention - Healthy Subject, Prostate Carcinoma | Not applicable | Completed | Thomas Jefferson University | 149 | 2020-01-08 | 2026-01-27 |
| Effects of Alternative Healthy Eating Index-Based Diet on Inflammatory Markers and Breast Density in Healthy Participants Dietary Intervention, Dual X-ray Absorptiometry, Questionnaire Administration - Healthy Subject | Not applicable | Completed | Fred Hutchinson Cancer Center | 21 | 2019-10-28 | 2021-01-22 |
Showing 20 of 72. Sign in to see all of them.
Breast Neoplasms (5) · Carcinoma, Renal Cell (2) · Colorectal Neoplasms (2) · Head and Neck Neoplasms (2) · Neoplasms (2) · Pancreatic Neoplasms (2) · Apnea (1) · Brain Neoplasms (1) · Breast Carcinoma In Situ (1) · Carcinoma, Ovarian Epithelial (1) · Colonic Neoplasms (1) · Epilepsy (1) · Glioblastoma (1) · Hematologic Diseases (1) · Hematologic Neoplasms (1)
Neoplasms by Site (16) · Neoplasms (15) · Breast Diseases (6) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6) · Neoplasms by Histologic Type (5) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Neoplasms, Glandular and Epithelial (4) · Urogenital Diseases (4) · Carcinoma (3) · Colonic Diseases (3) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Gastrointestinal Diseases (3)
Early Intervention, Educational (7) · Methods (6) · Educational Status (5) · Magnetic Resonance Spectroscopy (4) · Behavior Therapy (2) · Glucosamine (2) · Magnetic Resonance Imaging (2) · Monitoring, Physiologic (2) · Tablets (2) · 1,2-dibenzoyl-tert-butylhydrazine (1) · Absorptiometry, Photon (1) · BPI-3016 (1) · Chlorpromazine (1) · Chondroitin Sulfates (1) · Clostridium perfringens epsilon-toxin (1)
M.D. Anderson Cancer Center (6) · Ohio State University Comprehensive Cancer Center (6) · Roswell Park Cancer Institute (5) · Fred Hutchinson Cancer Center (4) · City of Hope Medical Center (3) · Sihuan Pharmaceutical Holdings Group Ltd. (3) · Stanford University (3) · Aptorum International Limited (2) · Changchun GeneScience Pharmaceutical Co., Ltd. (2) · Givaudan France Naturals (2) · Hospices Civils de Lyon (2) · National Cancer Institute (NCI) (2) · Staidson (Beijing) Biopharmaceuticals Co., Ltd (2) · University of Southern California (2) · Wake Forest University Health Sciences (2)
United States (43) · China (10) · France (5) · South Korea (4) · Belgium (1) · Canada (1) · India (1) · Israel (1) · Italy (1) · Japan (1) · Netherlands (1)
Alexander V Prokhorov (2) · Johanna Lampe (2) · Paul Reiter, PhD (2) · Thomas Lee, PhD (2) · Andrei Iagaru (1) · Anurag Singh (1) · Betty Ferrell (1) · Casey O'Connell, MD (1) · Charles Tomek, MD (1) · Clifton D Fuller (1) · David Bell (1) · David Spiegel (1) · Deborah Erwin (1)
PMID 30617093, PMID 26300719, PMID 29331245, PMID 29979642, PMID 30231854, PMID 30322833, PMID 30989436, PMID 31773209, PMID 31938892, PMID 31963708, PMID 32130192, PMID 32166864, PMID 32773377, PMID 32808383, PMID 32819883, PMID 33353412, PMID 34016140, PMID 34729628, PMID 34822339, PMID 37083300, PMID 37660952, PMID 38349618, PMID 38723214, PMID 39752644, PMID 40392756, PMID 40602721, PMID 41461276, PMID 42176992, PMID 42394970
P30CA016058 (3), P30CA012197 (2), P30CA014089 (2), 2018 (1), K07CA175115 (1), N01CN35153 (1), P30CA006927 (1), P30CA013330 (1), P30CA014520 (1), P30CA016056 (1), P30CA016672 (1), P30CA072720 (1), P30CA124435 (1), P50CA097190 (1), P50CA180906 (1)